Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis.

abstract：:Quality of life has become an important end point in clinical trials and academic studies. The questionnaires developed by the European Organisation for Research and Treatment of Cancer Quality of Life Group are widely used to measure quality of life in cancer patients. The expanding geographical coverage of current s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuliś D,Arnott M,Greimel ER,Bottomley A,Koller M,European Organisation for Research and Treatment of Cancer Quality of Life Group.

更新日期：2011-06-01 00:00:00

abstract：:Prostate cancer is the most common non-skin cancer in American men, and prostate-specific antigen (PSA) testing is its common screening procedure. In May 2012, the US Preventive Services Task Force recommended against PSA-based screening. These recommendations contradict the current recommendations of other organizati...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Garg V,Gu NY,Borrego ME,Raisch DW

更新日期：2013-06-01 00:00:00

abstract：:The second symposium of the European Organisation for Research and Treatment of Cancer took place in September 2011 at the European Parliament in Brussels (Belgium). The aim of the symposium was to discuss a wide range of topics in health-related quality of life, symptom research and cancer clinical trials, including ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Dormer L

更新日期：2011-12-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurodegenerative disease. There are no clinical trials comparing all available pharmacological therapies for the treatment of early PD. The objective of this review is to indirectly analyze the efficacy of antiparkinson drugs currently available in Latin America. A s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Márquez-Cruz M,Díaz-Martínez JP,Soto-Molina H,De Saráchaga AJ,Cervantes-Arriaga A,Llorens-Arenas R,Rodríguez-Violante M

更新日期：2016-01-01 00:00:00

abstract：:At least 14% of cancer patients live with minor children. Being a parent with cancer has far-reaching consequences for individual treatment decision-making and quality of life in patients and their families. Even though the majority of children and adolescents do not show clinically relevant symptoms of psychopatholog...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Krauel K,Simon A,Krause-Hebecker N,Czimbalmos A,Bottomley A,Flechtner H

更新日期：2012-12-01 00:00:00

abstract：:Despite the intense debates over state or private sector dominance in healthcare finance and provision, there are no clear winners. Failed models exist on either end of the ideological spectrum and no country in the world has one that is purely public or purely private. Neither does a perfect public-private mix exist;...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lim MK

更新日期：2006-12-01 00:00:00

abstract：:Ankylosing spondylitis (AS) is a complex systemic rheumatological disease which often causes severe disability and impaired quality of life (QoL). We searched the PubMed/MEDLINE electronic database for available literature on QoL and its predictors in patients with AS. Recent evidence indicates that AS patients have p...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kotsis K,Voulgari PV,Drosos AA,Carvalho AF,Hyphantis T

更新日期：2014-12-01 00:00:00

abstract：:We surveyed US-based leaders in health economics and outcomes research (HEOR) departments in drug and device companies to examine their views on the state of the field. We created a questionnaire that was emailed to 123 US-based senior HEOR professionals at 54 companies. Of the 123 recipients, 74 (60%) completed the s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Neumann PJ,Saret CJ

更新日期：2013-10-01 00:00:00

abstract：:Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of mortality worldwide. The chronic progressive disease is accompanied by a high loss of health-related quality of life (HRQoL). The available drugs usually only have symptomatic effects; therefore, non-pharmacological therapies are ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hindelang M,Kirsch F,Leidl R

更新日期：2020-02-01 00:00:00

abstract：:The purpose of this article is to provide a critical evaluation of the available literature describing the economic burden of multiple sclerosis and to assess the gaps in information. The studies included in this review describe costs in patients categorized into severity groups according to the Expanded Disability St...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Orlewska E

更新日期：2006-04-01 00:00:00

abstract：OBJECTIVES:Assess the efficiency of biologic treatment for moderate to severe ulcerative colitis (UC) which are indicated and financed for this pathology by Spain. METHODS:A Markov model was constructed to simulate the progression in a cohort of patients with moderate to severe UC. The perspective chosen was National ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Trigo-Vicente C,Gimeno-Ballester V,Montoiro-Allué R,López-Del Val A

更新日期：2018-06-01 00:00:00

abstract：:This review considers some of the broad principles that concern quality of life assessment. These are discussed in relation to health-related quality of life (HRQOL) and the measurement of subjective well-being. It is argued that there are serious logical and methodological issues concerning HRQOL measurement, to the ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Cummins RA,Lau AL,Stokes M

更新日期：2004-08-01 00:00:00

abstract：INTRODUCTION:This article is part of the series "How to Prepare a Systematic Review (SR) of Economic Evaluations (EE) for Informing Evidence-based Healthcare Decisions" in which a five-step-approach for conducting a SR of EE is proposed. Areas covered: This paper explains the data extraction process, the risk of bias a...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wijnen B,Van Mastrigt G,Redekop WK,Majoie H,De Kinderen R,Evers S

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Rotavirus diarrhea is a major health problem among young children worldwide with potential negative impacts on health-related quality of life (HRQoL). This study assessed the impact of rotavirus diarrhea on HRQoL of children and their caregivers. METHODS:We performed a cross-sectional study among 460 hospit...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Rochanathimoke O,Riewpaiboon A,Postma MJ,Thinyounyong W,Thavorncharoensap M

更新日期：2018-04-01 00:00:00

abstract：:In 2001, the US National Cancer Institute created the Cancer Outcomes Measurement Working Group (COMWG) to assess the state-of-the-science of outcomes assessment in cancer and to make recommendations for moving the field forward. The COMWG focused on methods for assessing patient-reported outcomes (health-related QoL,...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Snyder C,Gotay CC,Lipscomb J

更新日期：2006-08-01 00:00:00

abstract：OBJECTIVES:This cross-sectional study examined the prevalence and burden of major depressive disorder (MDD) among adults in urban China. METHODS:Data were included from the 2012 China National Health and Wellness Survey. Respondents self-reporting physician diagnosis of depression and screening positive for MDD (Patie...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gupta S,Goren A,Dong P,Liu D

更新日期：2016-06-01 00:00:00

abstract：:Evaluation of: Levin LA, Wallentin L, Bernfort L et al. Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes results from the PLATO trial. Value Health 16(4), 574-580 (2013). Antiplatelet therapy is considered essential treatment for acute coronary syndromes with or...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： De Franco AC,Oldridge N

更新日期：2014-02-01 00:00:00

abstract：INTRODUCTION:For optimum results from pharmacological management of overactive bladder, adherence to prescribed medication is required. Overactive bladder treatment has been compromised by low adherence and persistence to medications, losing many people who might benefit from treatment and exposing them to unnecessary ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Wagg A

更新日期：2016-08-01 00:00:00

abstract：:This article reviews the literature reporting empirically determined symptom clusters in patients with metastatic cancer. A literature search was conducted on symptom clusters within heterogeneous metastatic cancer patient populations using MEDLINE, EMBASE, and CINAHL. Studies examining predetermined symptom clusters ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Thavarajah N,Chen E,Zeng L,Bedard G,Di Giovanni J,Lemke M,Lauzon N,Zhou M,Chu D,Chow E

更新日期：2012-10-01 00:00:00

abstract：:Nursing homes are facing increased environmental pressures to improve quality of care. However, this increased emphasis on quality comes at a time when nursing homes are facing revenue constraints as a result of the repeal of the Boren amendment, increased reimbursement based on prospective payment systems and widespr...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Weech-Maldonado R,Mor V,Oluwole A

更新日期：2004-02-01 00:00:00

abstract：:Rheumatoid arthritis is a chronic inflammatory musculoskeletal disease with a prevalence rate of 1-3% in Western countries. In addition to limited physical function, rheumatoid arthritis patients also suffer from psychologic comorbidities. Depression in rheumatoid arthritis patients has been linked to disease outcomes...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Nichol MB,Zhang L

更新日期：2005-10-01 00:00:00

abstract：:Given growing interest in multicriteria decision making and multiple cost-effectiveness thresholds' approach, it was decided to investigate its usefulness in Poland. The pricing and reimbursement (P&R) regulations were reviewed and a cross-sectional survey was conducted amongst nurses. The study investigated whether P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kolasa K

更新日期：2014-10-01 00:00:00

abstract：:Respiratory syncytial virus is the most common cause of bronchiolitis, a lower respiratory tract infection occurring in infancy. It is responsible for several rehospitalizations, substantial morbidity and occasional deaths in the UK every year. Palivizumab is a recombinant monoclonal antibody that has been shown to re...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Embleton ND,Dharmaraj ST,Deshpande S

更新日期：2007-10-01 00:00:00

abstract：:Alzheimer's disease is a neurodegenerative disorder characterized by cognitive and behavioral deficits. Donepezil and memantine are two medications used to treat the symptoms of cognitive decline in Alzheimer's disease. A modeled cost-effectiveness analysis found that treatment with donepezil to be less costly and mor...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Oremus M,Tarride JE

更新日期：2012-06-01 00:00:00

abstract：:Chronic obstructive pulmonary disease is a progressive disease of the airways in which respiratory symptoms aggravate transitorily during disease exacerbations. The treatment of the disease in its stable state is the most important factor in reducing related morbidity, but exacerbation therapy might also impact on sub...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoniu SA

更新日期：2009-08-01 00:00:00

abstract：:The assessment of longitudinal change in subjective patient-reported outcomes such as health-related quality of life (HRQoL) is a key component of many clinical and research evaluations. A major goal of measuring patient-reported HRQoL is to determine to what extent changes in HRQoL reports over time represent true ch...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hamidou Z,Dabakuyo TS,Bonnetain F

更新日期：2011-10-01 00:00:00

abstract：:The main analytic problems for assessing the equality of means of healthcare costs are the skewed and heteroscedastic nature of the distribution of healthcare costs and the occurrence of persons with zero cost values. Without taking these special features into consideration, any statistical method may lead to the wron...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Zhou XH,Ramsey S

更新日期：2003-10-01 00:00:00

abstract：:Descemet's stripping endothelial keratoplasty (DSEK) is a relatively new technique that is rapidly replacing full-thickness procedures for those patients needing corneal transplantation for endothelial dysfunction. Benefits of DSEK include a faster recovery, reduced astigmatism, fewer postoperative complications and r...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kharod BV,Carlson AN

更新日期：2007-04-01 00:00:00

abstract：OBJECTIVE:To assess changes in the involvement of advisory bodies in the reimbursement decision-making process in Poland, and to evaluate variables that influenced HTA recommendations in the years 2013-2015. RESEARCH DESIGN AND METHODS:Two independent contributors reviewed the statements of the TC, recommendations iss...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kawalec P,Malinowski KP,Trąbka W

更新日期：2018-04-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurological disease affecting older adults. Consequently, this disease should be a focus among payers, with increasing utilization of newer premium-priced patent-protected add-on therapies to stabilize or even improve motor function over time. However, expenditure ca...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brkicic LS,Godman B,Voncina L,Sovic S,Relja M

更新日期：2012-06-01 00:00:00